Catheter Precision Inc (VTAK) concluded trading on Wednesday at a closing price of $0.30, with 5.55 million shares of worth about $1.67 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -35.74% during that period and on May 21, 2025 the price saw a gain of about 7.90%. Currently the company’s common shares owned by public are about 11.02M shares, out of which, 10.32M shares are available for trading.
Stock saw a price change of 1.34% in past 5 days and over the past one month there was a price change of -1.31%. Year-to-date (YTD), VTAK shares are showing a performance of -33.04% which decreased to -94.82% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.24 but also hit the highest price of $8.40 during that period. The average intraday trading volume for Catheter Precision Inc shares is 285.81K. The stock is currently trading 5.93% above its 20-day simple moving average (SMA20), while that difference is down -6.54% for SMA50 and it goes to -42.50% lower than SMA200.
Catheter Precision Inc (AMEX: VTAK) currently have 11.02M outstanding shares and institutions hold larger chunk of about 5.34% of that.
The stock has a current market capitalization of $3.33M and its 3Y-monthly beta is at -0.72. It has posted earnings per share of -$9.29 in the same period. It has Quick Ratio of 0.19 while making debt-to-equity ratio of 1.53. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VTAK, volatility over the week remained 9.73% while standing at 11.81% over the month.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Jaffray on August 13, 2019 offering a Neutral rating for the stock and assigned a target price range of between $9 and $1.50 to it. Coverage by Maxim Group stated Catheter Precision Inc (VTAK) stock as a Buy in their note to investors on November 02, 2018, suggesting a price target of $23 for the stock.
